Life Sciences

AION Labs CEO, Mati Gill, discusses the company’s extensive backing from pharma and tech giants to build AI startups, and how AION is looking beyond AI to explore quantum technologies for research and development in drug discovery.

AION Labs CEO sat down with MobiHealthNews outside the JPM Healthcare Conference to discuss the acquisition he says represents a milestone for Israel’s biotech ecosystem.

Outside the JPM Healthcare Conference, Thomas Clozel, cofounder and CEO of Owkin, sat down with MobiHealthNews to discuss how the company is using AI to find causality in disease.

The San Francisco-based lab will house Eli Lilly experts in biology, science and medicine alongside NVIDIA AI model builders and engineers.

Private rheumatologist Dr Anandita Santosa in Singapore notes how current AI in healthcare priorities practically leave autoimmune and rheumatic diseases behind and shares what can be done to build a more comprehensive AI-driven preventive care ecosystem.

The digital pharmacy will sell the newly FDA-approved weight-loss pill nationwide, allowing patients to pay through their insurance or in cash.

While HIMSS Media editors anticipate that AI will be used in every layer of healthcare's tech stack in 2026, they stress that governance and human oversight are essential to ensure AI works safely at scale.

Pharma faces regulations and stringent rules for transparency, but the payoff is drugs that can get to market faster and possibly at less expense.

Amgen, Bristol Myers Squibb, Boehringer Ingelheim, Genentech, Gilead Sciences, GSK, Merck, Novartis and Sanofi will sell medicines at a discounted price on TrumpRx.

Also, University of Queensland research has found ultrasound to be a safe approach to possibly treat symptoms of Alzheimer's disease in a world's first in-human trial.